[PDF] Top 20 Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
Has 10000 "Rev. Bras. Hematol. Hemoter. vol.30 suppl.2" found on our website. Below are the top 20 most common "Rev. Bras. Hematol. Hemoter. vol.30 suppl.2".
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... This supplement, the fourth issue this year of the Brazilian Journal of Hematology and Hemotherapy (RBHH), is focused on the Annual Meeting of the Italo-Brazilian Hematology Association [r] ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... and 2) combining rituximab with ...of 2 or 3 and age younger than 60 years, are characterized by truly refractory disease, evidenced by progression during or early after treatment, or later ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... The most striking observation of these first phase studies was that therapeutic evolution has markedly improved the CR probability, but this fact did not translate into a significative improvement of the outcome. ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... Older adults with Acute Myeloid Leukaemia (AML), when compared to younger patients with the same disease, have a poor prognosis and represent a discrete population in terms of disease biology, treatment-related ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... Minimal residual disease (MRD) was monitored in 80 patients with acute lymphoid (ALL, n=44) or myeloid (AML, n=36) leukemia, undergoing allogeneic haemopoietic stem cell transplantations. MRD markers were IgH-VDJ and TCR ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... after 2 to 21 days of treatment and were generally associated with increasing white blood cell (WBC) count and combined fever, weight gain, dyspnea, pleural effusion, and pulmonary infiltrates on chest radiograph ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... In face of the good metabolic results presented, the adverse effects were acceptable. With respect to acute complications, most patients had febrile neutropenia, nausea, vomiting and alopecia due to the immunosuppressive ... See full document
5
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... mechanism of action of GNF 2 is not yet fully characterized, its selectivity for BCR-ABL suggests that this agent may not present off-target effects and significant toxicity. Finally, LBH589 (Novartis) is a novel ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... This supplement, the fourth issue this year of the Brazilian Journal of Hematology and Hemotherapy (RBHH), is focused on the Annual Meeting of the Italo-Brazilian Hematology Association [r] ... See full document
2
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... O mieloma múltiplo (MM) é uma doença maligna das células plasmáticas caracterizada pelo acúmulo de células plasmáticas na medula óssea (MO). As células do MM interagem com o micro- ambiente e induzem modificações ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... The Durie/Salmon staging system continues to be used worldwide in patients with multiple myeloma. However, in recent years, new systems have been proposed. The International Myeloma Working Group performed a ... See full document
4
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... O transplante alogênico de célula-tronco hematopoética permane- ce como a única terapêutica com potencial terapêutico para a LMC in todas as fases da doença. Entretanto, os resultados com a utiliza- ção do mesilato de ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... Hemopoietic progenitor cells give rise to all cellular elements of the blood and are of importance as a potential source of cells used for correction of various pathological conditions. The main objective of this study ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.30 suppl.2
... neuropathy (7%), fatigue (6%) and constipation (1%) were more prominent in the thalidomide group, while the incidence of thromboembolic events was not significantly different in the 3 arms. A recently randomized trial ... See full document
8
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... Esta revisão focaliza os mais recentes avanços no diagnóstico e prognóstico da leucemia linfoblástica aguda do adulto e suas implicações no manuseio clínico desta doença. Com o passar dos anos, informações obtidas ... See full document
7
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... A major concern when treating APL patients is the necessity of prompt ATRA administration on suspicion. This can partially revert the coagulopathy and improve outcomes. Concomitantly, an interesting point is to avoid ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... 2 Gy TBI with or without fludarabine and allograft from HLA-identical siblings. Post-grafting immunosuppression was cyclosporine or tacrolimus and mycophenolate. Median follow-up was 6.3 years. Forty-two percent ... See full document
6
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... 4. Oshima K, Kanda Y, Nannya Y, Kaneko M, Hamaki T, Suguro M, et al. Clinical and pathologic findings in 52 consecutively autopsied cases with multiple myeloma. Am J Hematol. 2001;67(1):1-5. 5. Kraut EH, Sagone AL ... See full document
3
Rev. Bras. Hematol. Hemoter. vol.32 suppl.2
... de 30 profissionais de diversas especialidades médicas (hematologia e hemoterapia, gastroenterologia, pediatria, neonatologia, cardiologia, nefrologia, oncologia, geriatria, patologia clínica, obstetrícia e ... See full document
1
Rev. Bras. Hematol. Hemoter. vol.31 suppl.2
... In recent years, chemoimmunotherapies that combine cytotoxic agents and monoclonal antibodies have been studied intensively for the treatment of B-cell chronic lymphocytic leukemia (CLL). Of particular interest are ... See full document
6
temas relacionados